CP Reports Store

Current Partnering is the market-leading publisher of pharmaceutical and biotechnology dealmaking intelligence reports covering licensing agreements, collaboration agreements, co-development deals, M&A transactions, strategic alliances and partnering activity across the life sciences industry.

Our reports provide detailed analysis of real-world deal structures and financial terms, including upfront payments, milestone payments, royalty rates, equity investments and option-based deal mechanisms. Drawing on thousands of disclosed agreements, the reports enable business development and licensing professionals to benchmark comparable transactions and understand how partnerships are structured across therapeutic areas, technologies and company types.

Beyond financial terms, Current Partnering tracks key contractual provisions including exclusivity arrangements, geographic and territorial rights, regional licensing structures, development and commercialization responsibilities, co-promotion rights, manufacturing rights, intellectual property provisions and rights allocation between partners. This enables users to evaluate not only deal value but also how strategic control, risk and commercial opportunity are distributed between parties.

Coverage spans a broad range of therapeutic areas and technologies, including oncology, immunology, rare diseases, cell therapy, gene therapy, antibody-drug conjugates (ADCs), RNA therapeutics, vaccines and precision medicine.

Reports are widely relied upon globally by business development, licensing, corporate strategy, competitive intelligence and executive leadership teams to identify partners, benchmark transactions and support dealmaking decisions with real-world market evidence.

Browse our deal reports by: Deal Structure | Therapy | Technology | Development Stage | Industry | Annual Subscriptions

Items 1-10 of 68

Set Ascending Direction
  1. Regenerative Medicine Collaboration and Licensing Deals 2019-2026
    Regenerative Medicine Collaboration and Licensing Deals 2019-2026
    June 2026
    $4,995.00

    Regenerative Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2026

    Learn More
  2. Bioinformatics Collaboration and Licensing Deals 2019-2026
    Bioinformatics Collaboration and Licensing Deals 2019-2026
    May 2026
    $4,995.00

    Bioinformatics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2026

    Learn More
  3. Biomarker Collaboration and Licensing Deals 2016-2026
    Biomarker Collaboration and Licensing Deals 2016-2026
    May 2026
    $3,995.00

    Biomarker Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

    Learn More
  4. Precision Medicine Collaboration and Licensing Deals 2019-2026
    Precision Medicine Collaboration and Licensing Deals 2019-2026
    May 2026
    $4,995.00

    Precision Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2026

    Learn More
  5. Diagnostic Collaboration and Licensing Deals 2020-2026
    Diagnostic Collaboration and Licensing Deals 2020-2026
    May 2026
    $4,995.00

    Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2020 to 2026

    Learn More
  6. Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2026
    Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2026
    May 2026
    $3,995.00

    Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

    Learn More
  7. Infectious Vaccine Collaboration and Licensing Deals 2016-2026
    Infectious Vaccine Collaboration and Licensing Deals 2016-2026
    May 2026
    $3,995.00

    Infectious Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

    Learn More
  8. Monoclonal Antibody Collaboration and Licensing Deals 2019-2026
    Monoclonal Antibody Collaboration and Licensing Deals 2019-2026
    May 2026
    $3,995.00

    Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

    Learn More
  9. Antibiotic Collaboration and Licensing Deals 2016-2026
    Antibiotic Collaboration and Licensing Deals 2016-2026
    May 2026
    $3,995.00

    Antibiotic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026

    Learn More
Page
per page